cyrilzakka/clinical-trials huggingface dataset:
Reliability, Validity of The Turkish Version of Craniofacial Pain and Disability Inventory

This study, we are aim to make the Turkish version validity and reliability of the Cranifacial Pain and Disability Inventory, Jaw Functional Limitation Scale-20, and Jaw Functional Limitation Scale-8.

Approximately 60% of individuals with temporomandibular disorders (TMD) reported increased pain intensity from midlevel to severe. This was seen at the end of the intervention or work related activities in the quarter of individuals. Therefore, the correct diagnosis of TMD is very important to reduce the economic cost. Craniofacial Pain and Disability Inventory (CF-PDI) is designed based on a biopsychosocial approach. Evidence has shown that CF-PDI is an well-structured, internal consistency, repeatable and valid, and that an objective outcome for the evaluation of pain and discomfort in patients with craniofacial pain. There is no Turkish version and validity study of CF-PDI. Each item is scored between 0-3. The total score ranged from 0 to 63, and a high score indicate a high level of discomfort. The aim of this study was to evaluate the validity and reliability of the Turkish version of CF-PDI. The study of validity and reliability is planned with 105 individuals with TMD. The sociodemographic characteristics of the individuals will be questioned by the investigators and then the patients will be evaluated with CF-PDI, Neck Disability Index (NDI), Tampa Scale for Kinesiophobia (TSK), Pain Catastrophizing Scale (PCS), Headache Impact Test-6 (HIT-6), Jaw Functional Limitation Scale (JFLS) (Turkish version) and Visual Analogue Scale (VAS). The test-retest will be re-administered by face-to-face interview technique after 1 week. The results will be analyzed using the SPSS version 22.0 computer package program.

Eligibility Criteria:
Inclusion Criteria:

* Having a temporomandibular disorder
* Individuals who suited Temporomandibular Disorders/ Research Diagnostic Criteria classification

Exclusion Criteria:

* Pregnant,
* Canser,
* Trauma,
* Neurologic disorder,
* Infection,
* Trigeminal or postherpatic neuralgia
Symptoms and Mechanisms of Child Psychiatric Disorders

In this study the investigators will examine psychiatric symptoms, central neurocognitive functions, parental stress and attachment styles, and biological factors that can give new knowledge about some of the mechanisms present in children referred to outpatient psychiatric clinics. A specific focus will be given to children suffering from severe irritability.

In this study the investigators will examine psychiatric symptoms, central neurocognitive functions, parental stress and attachment styles, and biological factors that can give new knowledge about some of the mechanisms present in children referred to outpatient psychiatric service. A specific focus will be given to children suffering from severe irritability making problems at home, in school, and/or with peers.

Disruptive Mood Dysregulation Disorder (DMDD) is characterized by chronic and severe irritability and anger in children. DMDD understood as severe or clinical irritability can be regarded as laying above a certain threshold on a irritability continuum. Due to DMDD being a relatively new and debated diagnosis there is an urgent need to gain better understanding of the underlying mechanisms of severe irritability in children.

This study will explore emotion and behavior symptoms, neuropsychological functions (including social perception), perceived parental stress and attachment styles, and cortisol levels of children and their mothers, in children referred to outpatient psychiatric service including children with severe irritability. Parents of children 6 to 12 years will be informed and asked to participate.

The work on severe irritability will be divided into six main areas:

1. Severe irritability in a Norwegian clinical population: prevalence, comorbidity and associated difficulties
2. Social and emotional understanding in severe irritability in children
3. Executive function in severe irritability in children
4. Stress response in severe irritability in children
5. Parental stress and attachment style in parents of severe irritability in children
6. DMDD: An affective or conduct disorder? Comparing anxiety and depressive symptoms

Eligibility Criteria:
Inclusion Criteria:

* Referred to outpatient psychiatric service
* Intelligence quotient (IQ) within normal range
* Child and parents: Good enough understanding of Norwegian language to give valid answers in interview and tests.
* Clarified care situation

Exclusion Criteria:

* IQ below normal range
* Child and parents: Not good enough understanding of Norwegian language to give valid answers in interview and tests
* Unclarified care situation
TGV:Use of the Quick Diagnostic Test of the Influenza and the Infection With RSV by the Paediatric Emergency Unit

The aim of this study is to evaluate the impact of the use of a quick diagnostic test of infection with RSV and influenza virus on the assumption of clinical responsibility of the children consulting at the Paediatric Emergency Unit.


Eligibility Criteria:
Inclusion Criteria:

* Age less than 5 years
* Isolated fever and/or
* Infection of the higher air routes (congestive otitis, feverish rhinitides, tracheitis or laryngitis) and/or infection of the lower air routes (cough, pneumonia, bronchitis, asthma)
* Signed consent form

Exclusion Criteria:

* Evocative clinical of a urinary and/or bacterial infection
* Purulent acute otitis media
* Typical acute bronchiolitis
* Suspicion of acute lobar pneumonia
* Acute gastro-enteritis
* Anginas
* Serious chronic respiratory pathology
* Other infection whose etiologic viral diagnosis is established
* Congenital or acquired immunizing deficits
* Congenital cardiopathy
Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain

This study will compare the pain relieving effect of a single-dose of a novel ibuprofen formulation to placebo and two formulations of standard ibuprofen in the treatment of post-surgical dental pain following "wisdom" tooth (third molar) removal.


Eligibility Criteria:
Inclusion Criteria:

* Normal, healthy males and females 16 to 40 years of age
* Outpatients who have moderate to severe post-operative pain (confirmed by a Visual Analog Scale-Pain Severity Rating \[VAS-PSR\] score of at least 50 mm on a 100 mm VAS-PSR) following surgical extraction of two or more third molars, at least one of which must be a partial or complete bony mandibular impaction
* Use of only the following pre-operative medication(s)/anesthetic(s): topical benzocaine, a short acting parenteral (local) anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor and/or nitrous oxide

Exclusion Criteria:

* Pregnancy or breast-feeding
* Alcohol or substance abuse
* Any serious medical or psychiatric disorder
* History of stomach ulcers, stomach bleed, or other bleeding disorders
* Use of a prescription or over-the-counter drug with which administration of ibuprofen or any other non-steroidal anti-inflammatory drug, acetaminophen, or hydrocodone is contraindicated (including: opioids, antipsychotics, antianxiety agents, or other central nervous system depressants\[including alcohol\])
Bilateral Internal Iliac Artery Ligation Before Cesarean Hysterectomy

All women with placenta accreta will be managed by upper segment cesarean section followed by cesarean hysterectomy without attempts of placental removal.

Women were randomized to either bilateral internal iliac artery ligation before hysterectomy and after fetal extraction or no additional intervention

All women with placenta accreta will be managed by upper segment cesarean section followed by cesarean hysterectomy without attempts of placental removal.

Women were randomized to either bilateral internal iliac artery ligation before hysterectomy and after fetal extraction or no additional intervention.

Midline incision in the all patients is preferred. The retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. The ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. The fat and loose connective tissue around the IIA and vein were removed and a right-angle clamp was passed beneath the IIA from the lateral to the medial side approximately 4 cm distal to its origin.

Using an absorbable suture, the IIA was ligated doubly in all cases . Pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. The procedure was then repeated on the other side.

Eligibility Criteria:
Inclusion Criteria:

* women with suspected placenta accreta
* Scarred uterus
* Approving hysterectomy

Exclusion Criteria:

* Women needed conservative surgery
* women with coagulopathy or bleeding disorders
Reaching Clinical Recommendations for Intensity of Post-stroke Rehabilitation

The project aims to implement workstations for mobility training during intensive inpatient rehabilitation to increase the level of motor activity of individuals with hemiparesis due to stroke


Eligibility Criteria:
Inclusion Criteria:

* Receving intensive rehabilitation care for hemiparesis due to stroke in our rehabilitation facility (IRGLM)

Exclusion Criteria:

* Cognitive deficits preventing participation to rehabilitation
Prostasomes as Diagnostic Tool for Prostate Cancer Detection

Prostate cancer is the most frequently diagnosed cancer among men over 50 years old in Western societies, with an incidence that is steadily increasing in most countries. The current, most commonly used biomarker for prostate cancer is prostate specific antigen (PSA), which has well known limitations in accuracy and requires additional testing. However, prostate cancer cells secrete exosomes, also known as prostasomes, which are only detectable in the blood of prostate cancer patients. The presence of prostasomes in the blood is in itself a prostate cancer diagnosis. However, the assay that has been designed for the purification of prostasomes requires additional testing for evaluating its robustness and usefulness in the clinical setting. Additionally, the evaluation of the cargo of the purified prostasomes may provide more information on the nature of the prostate cancer, which may help develop a molecular assay for a prostate cancer liquid biopsy rather than a tissue biopsy. Therefore, the purpose of this study is two-fold: a validation phase where the purification of prostasomes will be tested on plasma collected from prostate cancer patients and a molecular testing phase where the contents of the purified prostasomes will be evaluated on their ability to determine the grade of the prostate tumors.

We will collaborate with Dr. Masood Kamali-Moghaddam at the Uppsala University (Department of Immunology, Genetics and Pathology) for molecular assay processing.


Eligibility Criteria:
Inclusion Criteria:

* Male
* With elevated PSA or patients with diagnosed prostate cancer
* 18 years and older
* Willingness to participate in the study and compliance with protocol requirements
* Have not received any type of treatment for prostate cancer

Exclusion Criteria:

* Patients with confirmed or suspected prostate cancer that have already received any type of treatment
* Patients with another primary cancer within the past five years of prostate cancer diagnosis. However, superficial skin cancers such as basal cell or squamous cell cancers would not exclude a patient.
The Effect of the Combination of Cleanser and Moisturizer Product K

This study is conducted to evaluate the effectiveness of product K cleanser and moisturizer when use in combination for skin rejuvenation. The study duration is 8 weeks and the skin assessment will be carried out at baseline, week 2, week 4 and week 8.The main questions this study aims to answer are:

1. The effect of cleanser and moisturizer K when use in combination on skin hydration.
2. The effect of cleanser and moisturizer K when use in combination on skin elasticity.
3. To observe any adverse effect occurrence with the usage of the products.


Eligibility Criteria:
Inclusion Criteria:

* Malaysia citizen
* Male and female (age 20-60 years old)

Exclusion Criteria:

* Participants taking isotretinoin
* Immunocompromised patients
* Participant who undergo any cosmetic procedures such as laser \& light treatment for the past three months.
* Participant with a history of facial surgery.
Neurofeedback as a Treatment Tool for Depression

The purpose of the study is to investigate whether neurofeedback delivered via functional magnetic resonance imaging signals can be used to train depressed patients to self-regulate emotion networks and whether this improves clinical symptoms.


Eligibility Criteria:
Inclusion Criteria:

* major depressive disorder (MDD) diagnosis
* stable antidepressant dose medication

Exclusion Criteria:

* Other physical or psychiatric disorders
* Current substance abuse
* Current psychotherapy or other specific intervention
* Exclusion criteria applicable to MRI
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 \& 600 µg o.d.) in order to select two doses to carry forward into study Stage 2. Study Stage 2 will provide pivotal confirmation of efficacy, safety, and tolerability of the selected indacaterol doses in patients with COPD


Eligibility Criteria:
Inclusion Criteria:

* Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure
* Co-operative outpatients with a diagnosis of COPD (moderate to severe as classified by the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) Guidelines, 2005) and:

  * Smoking history of at least 20 pack years
  * Post-bronchodilator FEV1 \< 80% and ≥ 30% of the predicted normal value.
  * Post-bronchodilator FEV1/FVC \< 70% (Post refers to within 30 min of inhalation of 400 µg of salbutamol)

Exclusion Criteria:

* Pregnant or lactating females
* Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period
* Patients requiring long term oxygen therapy (\> 15 h a day)
* Patients who have had a respiratory tract infection 6 weeks prior to V1 (with further criteria)
* Patients with concomitant pulmonary disease, pulmonary tuberculosis, or clinically significant bronchiectasis
* Patients with a history of asthma (with further criteria)
* Patients with Type I or uncontrolled Type II diabetes
* Patients with contraindications for tiotropium
* Patients who have clinically relevant laboratory abnormalities or a clinically significant abnormality
* Any patient with active cancer or a history of cancer with less than 5 years disease free survival time
* Patients with a history of long QT syndrome or whose QTc interval is prolonged
* Patients with a hypersensitivity to any of the study drugs or drugs with similar chemical structures
* Patients who have had treatment with the investigational drug (with further criteria)
* Patients who have had live attenuated vaccinations within 30 days prior to visit 1, or during run-in period
* Patients with known history of non compliance to medication
* Patients unable to satisfactorily use a dry powder inhaler device or perform spirometry measurements

Other protocol-defined inclusion/exclusion criteria may apply
Pre-lemniscal Radiation Deep Brain Stimulation for ET

The hypothesis is that prelemniscal radiation (RaPRL) deep brain stimulation (DBS) is more effective for axial (head/neck/voice) tremor, and perhaps, appendicular tremor control in essential tremor patients.


Eligibility Criteria:
Inclusion Criteria:

1. diagnosis of essential tremor based on clinical criteria established by the Essential Tremor Consortium
2. Moderate or severe axial-dominant (head/neck/voice) tremor (Tremor Rating Scale \[TRS\] face, tongue, voice, head or trunk tremor score of 2 or above)
3. May have bilateral appendicular tremor
4. Tremor refractory to at least two medications, including primidone and propranolol
5. Age between 21 and 75
6. Male or Female
7. Significant disability due to essential tremor despite medical treatment (TRS score of 2 or above in any one of the items 16-23 \[speaking, feeding other than liquids, bringing liquids to mouth, hygiene, dressing, writing, working, and social activities\])

Exclusion Criteria:

1. Tremor due to other etiologies
2. Pregnancy
3. Presence of any other neurodegenerative disease
4. Presence of significant cognitive impairment
5. Presence of any medical condition that precludes neurological surgery
6. Patients with another implanted stimulator or metallic implant, e.g. cochlear implant, cardiac pacemaker, spinal cord stimulator, aneurysm clips
7. Patients who have a known need for future MRIs using a full body radio-frequency (RF) coil or a head transmit coil that extends over the chest area or that do not comply with Medtronic's "MRI Guidelines for Medtronic Deep Brain Simulation Systems"
8. Patients with a history of seizures
9. Patients with psychiatric illness that are not well controlled
10. Patients with risk factors for intraoperative or postoperative bleeding (platelet count less than 125,000 per cubic millimeter, PT and PTT not within normal limits)
11. Patients with brain tumors
Physical Activity and Bariatric Surgery

Bariatric surgery indeed leads to significant weight loss, reduces mortality risk, obesity-associated comorbidities (Wolfe et al., 2016) and improves functional physical abilities (Herring et al., 2016). Because these benefits are related to decreased energy intake, the investigators aim to optimize them by combining them with supervised adapted physical activity practice.

So, the aim of this clinical trial is to measure the effects of a physical training program on physical fitness, body composition and quality of life of obese women who have undergone bariatric surgery.

Upon hospitalization for their bariatric surgery (bypass or sleeve), subjects will sign their informed consent and be included in the study. Six weeks' post-surgery, the subjects will be randomized in one of the 2 groups (Control group CG or Adapted Physical Activity group APAG). Patients in both groups will have 3 postoperative visits one at 6 weeks (V1), one at 18 weeks (V2) and one at 30 weeks (V3). During these visits, they will undergo the same assessments (body composition, physical condition, quality of life). Patients in the CG will receive standard hospital management. Patients in APAG will follow the same management and will also follow a 3-month physical activity program 3 times a week between V1 and V2. Then, between V2 and V3, no APA program will be offered to both groups.

The subjects will evaluate during each visit V1, V2 and V3:

* body composition,
* physical condition,
* quality of life
* daily physical activity

Eligibility Criteria:
Inclusion Criteria:

* women between 18 and 55 years old
* undergoing bariatric surgery (a "bypass gastric" or a "sleeve")
* not practicing a supervised physical activity
* having read and signed an informed consent prior to the start of the trial
* being affiliated to a social security system

Exclusion Criteria:

* Women with a contraindication to physical activity
* any medical contraindication to the practice of stress tests.
* unable to go to the hospital regularly
* having a significant functional limitation that does not allow her to perform the 6-minute walk test
* with an intellectual disability and/or psychiatric illness
* does not speak and/or understand French
* pregnant woman
* under guardianship or curatorship
* participating in another clinical research
Left Ventricular Hypertrophy Among Chronic Kidney Disease Patients in Assiut University Hospital

Assess the prevalence and features of left ventricular hypertrophy in patients with chronic kidney disease (CKD) taking into account gender differences and stage of CKD.

To detect factors those predict LVH in CKD.

\*to assess the right ventricle dysfunction in CKD .

The number of patients with chronic kidney disease (CKD) is growing worldwide, while patients with impaired renal function are at high or very high risk for developing cardiovascular disease (CVD). Mortality due to CVD in patients with CKD is 1020 times higher than that in the general population, and the likelihood of developing cardiovascular complications (CVC) is several times higher than the risk of end-stage CKD{1} In CKD cardiovascular disease abnormalities are due to volume overload, hypertension, endothelia dysfunction, inflammation, uremic pericarditis cardiomyopathy, anemia, dyslipidemia and oxidativel stress{2} Left ventricular hypertrophy (LVH) is a key feature that allows you to get an accurate picture of systolic-diastolic lesions of the left heart in patients with CKD and therefore is one of the most important factors in the development of adverse CVC LVH is initially formed as an adaptive process aimed at maintaining normal heart function under conditions of myocardial overload by pressure or volume, but then acquires the character of pathological adaptation, becoming the structural basis of heart failure, myocardial ischemia and cardiac arrhythmias {3}. It was shown that the probability of LVH increases already with a moderate decrease in eGFR and increases further as CKD progresses, reaching a maximum in the terminal stage \[4\].

. in CKD LVH is associated with increased mortality and the risk of adverse outcomes, especially at the terminal stage of CKD{5-6}

Eligibility Criteria:
Inclusion Criteria:

- Patients with chronic renal disease (CKD) aged between 16 and 65 years will be included.

2- CKD are diagnosed based on criteria proposed by KDIGO (Kidney Disease: Improving Global Outcomes) in 2002

Exclusion Criteria:

* Patients with structural heart disease (congenital or valvular heart disease). Patients with primary hypertension. Patients with obstructive or restrictive lung disease.
Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects

To evaluate the absorption, metabolism and excretion of HMPL-523 in healthy male Chinese subjects following multiple oral doses of HMPL-523 tablets followed by a single oral dose of \[14C\]HMPL-523 suspension

a single-center, non-randomized, open-label, human mass balance, phase 1 study to evaluate the absorption, metabolism and excretion following multiple oral doses of HMPL-523 tablets, followed by a single oral dose of 300 mg/150 µCi \[14C\]HMPL-523 suspension in healthy adult male Chinese subjects.

Eligibility Criteria:
Inclusion Criteria:

1. Subjects who have voluntarily participated in the study and signed the informed consent form with good compliance;
2. Healthy male subjects aged 18-40 years (inclusive);
3. Subjects weighing ≥ 50 kg
4. Subjects in good health status

Exclusion Criteria:

1. Subjects with a history of gastrointestinal surgery, renal surgery, cholecystectomy and other procedures that in the judgment of the investigator may affect drug absorption or excretion
2. hypersensitivity to the investigational product and its excipients
3. Subjects with diseases affecting the absorption, distribution, metabolism and excretion of oral drugs,
4. Subjects with fear of needles, hemophobia, difficulty collecting venous blood, or special requirements for diet, who cannot comply with uniform diet
5. Subjects who are abnormal with clinical significance for C-reactive protein or positive for coronavirus nucleic acid detection in coronavirus infection screening
6. Subjects who have participated in another clinical trial of other drugs and have received such investigational product within 3 months prior to the first dose
7. Having any other diseases or conditions that may affect the normal performance of the study or the evaluation of the study data, or having other conditions that are not suitable for the study, as judged by investigators